Neurocrine Biosciences Inc

  • Health Care
  • Biotechnology: Biological Products (No Diagnostic Substances)
  • www.neurocrine.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $12.00B
  • PE 35
  • Debt $0.00
  • Cash $241.00M
  • EV $11.76B
  • FCF $557.20M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$341.30M
EBIT$570.50M
ROE13%
ROA15%
FCF$557.20M
Equity$2.59B
Growth Stability58%
PE35.15
PEG4.31
PB4.63
P/FCF21.53
P/S5.09
Price/Cash0.02
Debt/Equity0
Debt/FCF0
Net Margins14%
Gross Margins99%
Op. Margins24%
Earnings CAGR27%
Sales Growth YoY22%
Sales Growth QoQ1%
Sales CAGR76%
FCF CAGR51%
Equity CAGR27%
Earnings Stability0.21
Earnings Growth YoY-30%
Earnings Growth QoQ-21%
Earnings CAGR 5Y8%
Sales CAGR 5Y23%
FCF CAGR 5Y17%
Equity CAGR 5Y30%
Earnings CAGR 3Y27%
Sales CAGR 3Y27%
FCF CAGR 3Y79%
Equity CAGR 3Y30%
Market Cap$12.00B
Revenue$2.36B
Assets$3.72B
Total Debt$0.00
Cash$241.00M
Shares Outstanding99.4M
EV11.76B
Earnings Score12%
Moat Score94%
Safety Score84%
Final Score63%
Working Capital1.22B
Current Ratio3.4
Gross Profit$2.32B
Shares Growth 3y2%
Equity Growth QoQ-5%
Equity Growth YoY16%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

SEC Filings

Direct access to Neurocrine Biosciences Inc (NBIX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Neurocrine Biosciences Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Neurocrine Biosciences Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 27%
Stability 21%
loading chart...

Neurocrine Biosciences Inc Discounted Cash Flow

Fully customizable DCF calculator online for Neurocrine Biosciences Inc.

= $182B
012345678910TV
fcf$557M$843M$1.3B$1.9B$2.9B$4.4B$6.7B$10B$15B$23B$35B$349B
DCF$766M$1.1B$1.4B$2B$2.7B$3.8B$5.2B$7.1B$9.8B$13B$134B
Value$182B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-450%-941%-88%5%5%39%8%10%13%14%14%
ROA--39%-16%4%6%9%5%11%10%15%15%
ROE--45%-38%4%6%36%7%9%11%13%13%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF--0-3.655.075.951.461.440.520.4700
Debt over Equity-00.990.811.280.280.240.10.0800
Growth Stability------58%87%100%100%58%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth--24%978%179%75%33%8%31%27%25%23%
Earnings YoY growth-59%1%-115%75%1K%-78%72%62%37%8%
Equity YoY growth--26%18%29%32%77%22%24%31%16%30%
FCF YoY growth-176%-8%-176%79%58%7%39%12%54%17%